Torrent Pharmaceuticals Ltd.
NSE: TORNTPHARM · Pharmaceuticals
Snapshot
Unlock Torrent Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Torrent Pharmaceuticals Limited is a prominent Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic formulations. The company operates across diverse therapeutic areas including cardiovascular, central nervous system, gastrointestinal, and diabetology, while also providing contract manufacturing services.
Business Model
The company generates revenue through the sale of branded and generic pharmaceutical products across domestic and international markets. It further leverages licensing collaborations for specialized portfolios and provides contract manufacturing services to third-party clients.
Growth Outlook
Growth is driven by the expansion of its diverse therapeutic portfolio and strategic licensing agreements for specialized treatments. The company continues to focus on strengthening its presence in key international markets including the United States, Germany, and Brazil.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where non-compliance could lead to import bans or product recalls.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector and government-mandated price controls in India may compress profit margins.
- Currency Volatility. As a significant exporter to the US, Germany, and Brazil, the company is exposed to fluctuations in foreign exchange rates that can impact reported earnings.
- R&D Execution. The ability to successfully develop and commercialise new generic formulations in a timely manner is critical to maintaining market share against global peers.
Start your research today
Unlock AI insights, financials, peers and live data on Torrent Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹15,723 Cr
TTM · consolidated
NET PROFIT
₹2,156 Cr
TTM · consolidated
EPS
₹62.60
TTM · consolidated
RETURN ON EQUITY
27.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.1%
TTM · consolidated
P/E
77.6x
Q1 FY27 · consolidated
EV/EBITDA
38.7x
Q1 FY27 · consolidated
EBITDA MARGIN
32.6%
TTM · consolidated
NET PROFIT MARGIN
11.5%
Q1 FY27 · consolidated
DEBT TO EQUITY
1.8x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.85L Cr | 77.59 | 38.74 | 32.9% | 32.6% | 27.0% | 15.1% | +34.9% |
Divi's Laboratories Ltd.DIVISLAB | ₹2.42L Cr | 82.57 | 54.64 | 16.3% | 39.3% | 18.4% | 23.1% | +48.4% |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.13L Cr | 24.96 | 14.08 | 21.1% | 30.7% | 18.0% | 20.1% | +10.7% |
Cipla Ltd.CIPLA | ₹1.12L Cr | 33.18 | 18.12 | 1.8% | 21.6% | 10.2% | 13.6% | -12.2% |
Laurus Labs Ltd.LAURUSLABS | ₹99,334 Cr | 90.82 | 48.68 | 22.6% | 28.7% | 22.3% | 25.3% | +110.5% |
Lupin Ltd.LUPIN | ₹96,476 Cr | 17.44 | 9.81 | 28.2% | 33.4% | 28.0% | 34.5% | +8.8% |
As of Q1 FY27
Financials
Torrent Pharmaceuticals Ltd.
NSE: TORNTPHARM · Pharmaceuticals
Snapshot
Unlock Torrent Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Torrent Pharmaceuticals Limited is a prominent Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic formulations. The company operates across diverse therapeutic areas including cardiovascular, central nervous system, gastrointestinal, and diabetology, while also providing contract manufacturing services.
Business Model
The company generates revenue through the sale of branded and generic pharmaceutical products across domestic and international markets. It further leverages licensing collaborations for specialized portfolios and provides contract manufacturing services to third-party clients.
Growth Outlook
Growth is driven by the expansion of its diverse therapeutic portfolio and strategic licensing agreements for specialized treatments. The company continues to focus on strengthening its presence in key international markets including the United States, Germany, and Brazil.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where non-compliance could lead to import bans or product recalls.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector and government-mandated price controls in India may compress profit margins.
- Currency Volatility. As a significant exporter to the US, Germany, and Brazil, the company is exposed to fluctuations in foreign exchange rates that can impact reported earnings.
- R&D Execution. The ability to successfully develop and commercialise new generic formulations in a timely manner is critical to maintaining market share against global peers.
Start your research today
Unlock AI insights, financials, peers and live data on Torrent Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹15,723 Cr
TTM · consolidated
NET PROFIT
₹2,156 Cr
TTM · consolidated
EPS
₹62.60
TTM · consolidated
RETURN ON EQUITY
27.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.1%
TTM · consolidated
P/E
77.6x
Q1 FY27 · consolidated
EV/EBITDA
38.7x
Q1 FY27 · consolidated
EBITDA MARGIN
32.6%
TTM · consolidated
NET PROFIT MARGIN
11.5%
Q1 FY27 · consolidated
DEBT TO EQUITY
1.8x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27